Oriol Olive

TL;DR: The feasibility, safety, and immunogenicity of a vaccine that targets up to 20 predicted personal tumour neoantigens is demonstrated and a strong rationale for further development of this approach, alone and in combination with checkpoint blockade or other immunotherapies is provided.

TL;DR: It is demonstrated that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load and an immunologically ‘cold’ tumour microenvironment.

TL;DR: In this paper, the authors evaluated the long-term effects of personal neoantigen vaccines and found that they can induce durable and specific memory T cell clones that have cytotoxic gene signatures and can diversify to include non-vaccine specificities.

TL;DR: Analysis of growth dynamics in a dataset from 107 patients with chronic lymphocytic leukaemia reveals both exponential and logistic patterns of growth, which are associated with differences in genetic attributes and clinical outcomes.

TL;DR: This approach provides a means to identify and express TCRs, and then rapidly assess antigen specificity and functional avidity of a reconstructed TCR, which can be applied for monitoring antigen-specific T- cell responses, and potentially for guiding the design of effective T-cell-based immunotherapies.